Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Down 49.0% in July

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 119,800 shares, adeclineof49.0% from the July 15th total of 234,700 shares. Approximately0.0% of the shares of the stock are sold short. Based on an average daily volume of 2,074,300 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 2,074,300 shares, the short-interest ratio is presently 0.1 days. Approximately0.0% of the shares of the stock are sold short.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY stock remained flat at $8.11 during trading on Thursday. 135,504 shares of the company traded hands, compared to its average volume of 828,073. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.25 and a quick ratio of 0.79. The company has a market capitalization of $31.87 billion, a price-to-earnings ratio of -8.36 and a beta of 0.91. The business's fifty day moving average is $7.89 and its 200-day moving average is $6.85. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $8.65.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.25 by $0.10. The business had revenue of $12.42 billion during the quarter, compared to analysts' expectations of $10.79 billion. Bayer Aktiengesellschaft had a negative net margin of 7.61% and a positive return on equity of 15.48%. On average, equities analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Hsbc Global Res raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, June 11th. Kepler Capital Markets raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Wednesday, June 11th. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a "buy" rating to a "strong-buy" rating in a research report on Tuesday. Finally, The Goldman Sachs Group raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy".

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.